Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19

NCT05054114 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

630

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Respiratory Infection
Acute Respiratory Disease

Interventions

DRUG: Interferon gamma human recombinant (IFN-G)

Sponsor

SPP Pharmaclon Ltd.